Giá Molecules of Korolchuk IP-NFT
VITA-FASTLoại tiền điện tử này không được niêm yết để giao dịch hoặc cung cấp dịch vụ trên Gate.io.
Biểu đồ giá trực tiếp Molecules of Korolchuk IP-NFT (VITA-FAST)
Giá Molecules of Korolchuk IP-NFT (VITA-FAST) hôm nay
Giá của Molecules of Korolchuk IP-NFT (VITA-FAST) hôm nay là ₫111,360, với khối lượng giao dịch trong 24 giờ là ₫245.11M và do đó Molecules of Korolchuk IP-NFT (VITA-FAST) có vốn hóa thị trường là ₫111.36B, chiếm lĩnh thị trường với tỷ lệ +0%. Giá Molecules of Korolchuk IP-NFT (VITA-FAST) đã thay đổi -0.08% trong 24 giờ qua.
Dữ liệu giá VITA-FAST
- Khối lượng 24H₫245.11M
- Cao nhất lịch sử (ATH)₫724,072
- Cao 24H₫112,288
- Thấp nhất lịch sử (ATL)₫49,648
- Thấp 24H₫106,952
Thông tin vốn hóa thị trường VITA-FAST
- Vốn hóa thị trường₫111.36B
- Định giá pha loãng hoàn toàn₫111.36B
- Vốn hóa thị trường/FDV100%
- Tâm lý thị trườngTrung lập
Nguồn cung VITA-FAST
- Nguồn cung lưu thông1M VITA-FAST
- Tổng cung1M VITA-FAST
- Cung cấp tối đa1M VITA-FAST
Giới thiệu về Molecules of Korolchuk IP-NFT (VITA-FAST)
Hợp đồng
0x6034e0d...6a1d33d36
Khám phá
etherscan.io
Trang web
vitadao.com
Ghi chú
What is the project about?
VitaDAO, a decentralized autonomous organization, introduces VITA-FAST, an innovative funding model for longevity research. Leveraging the Ethereum blockchain, VITA-FAST are ERC-20 tokens, signifying fractional ownership of the Intellectual Property Non-Fungible Token (IP-NFT) from longevity research conducted at the Korolchuk Lab, Newcastle University. VITA-FAST token holders gain governance rights over the IP, democratizing the decision-making processes in scientific research.
1. What is the project about?
The project is focused on discovering and developing therapeutic compounds that can reactivate autophagy in Npc1 -/- cells. This involves screening bioactive and commercial small molecules in cell survival assays to identify potential autophagy activators that are not cytotoxic. The project uses advanced techniques like luciferase-p6 clearance and Halo-GFP-LC3 orthogonal assays for this purpose.
2. What makes your project unique?
The project's uniqueness lies in its approach to identifying novel compounds that can induce autophagy in NPC1 -/- cells, a crucial process for treating Niemann-Pick Type C disease. Unlike existing treatments, this project employs high-throughput screening methods and innovative assays to discover compounds with high chemical variability and no similarity to existing autophagy inducers, opening up possibilities for new iIP.
3. History of your project.
The project, led by Dr. Korolchuk and his team at Newcastle University, has progressed from generating data on thousands of compounds using advanced screening assays to identifying lead compounds with potential autophagic properties. It has evolved to include the synthesis of derivatives of these compounds and is now moving towards drug translation processes, including pharmacokinetics and scalability studies.
4. What’s next for your project?
The next steps involve screening third-generation compounds, conducting in vitro and in vivo mo